Cardiff Oncology (CRDF) Stock: Buy, Sell, or Hold?
CRDF - Cardiff Oncology, Inc. Common Stock
$1.09
0.01 (0.93%)
▲
5d:
+15.96%
30d:
+13.49%
90d:
-27.33%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When CRDF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CRDF shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CRDF shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CRDF is currently trading at $1.09, which is considered extended relative to its 30-day fair value range of $0.87 to $1.01.
Technical Outlook: Technically, CRDF is in a strong downtrend. The price is approaching resistance at $1.10. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRDF scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.28 (+384.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CRDF is in a strong downtrend. The price is approaching resistance at $1.10. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CRDF scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.28 (+384.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.87 -
$1.01
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range (+7.9% above its trading range)
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 384.7% below Wall St target ($5.28)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.87 -
$1.01
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.90
Resistance Level
$1.10
Current Trend
Strong Downtrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.81
Wall Street Target
$5.28
(+384.7%)
Revenue Growth (YoY)
-14.1%
Share & Embed Analysis
Last updated: September 05, 2026 5:03 PM ET
Data refreshes hourly during market hours. Next update: 6:03 PM
Data refreshes hourly during market hours. Next update: 6:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRDF showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 55 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 56 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
13 analysts |
$19 | 50 HOLD |
